What is Claimed is:

1. A pharmaceutical composition comprising, at least one of mammalian allogeneic mesenchymal stem cells and differentiated allogeneic mesenchymal stem cells that have been exposed to one or more activating agents *in vitro* or *ex vivo* for at least 2 hours selected from the group consisting of one or more Toll-like receptor 3 (TLR3) agonist selected from the group consisting of polyadenylic-polyuridylic acid (poly(A:U), polyinosine-polycytidylic acid (pIC), and UV-inactivated viral particles; a Toll-like receptor 9 (TLR9) agonist selected from the group consisting of CpG oligodeoxynucleotides (CpG ODNs), inhibitory oligodeoxynucleotides (ODNs), short single-stranded purified DNA, and short single-stranded purified or synthetic plasmid DNA; a Toll-like receptor 4 (TLR4) agonist selected from the group consisting of bacterial lipopolysaccharides (LPS) and monophosphoryl lipid A (MPLA) or heat killed Gram-negative bacteria, wherein the activated mesenchymal stem cells are capable of treating a wound in a subject having at least one of a drug resistant bacteria and a mixed bacterial population; and one or more pharmaceutically acceptable carriers, diluents, or excipients.

2. The composition of claim 1, wherein the composition is formulated for intravenous administration.

3. The composition of claim 2, wherein the allogeneic mesenchymal stem cells or differentiated allogeneic mesenchymal stem cells (iMSCs) are obtained or harvested from bone marrow, adipose tissue, blood, cord blood, umbilical cord tissue, placenta, tissue biopsies, dental biopsies, skin biopsies or induced pluripotent stem cells (iPSC).

4. The composition of claim 1, wherein the allogeneic mesenchymal stem cells or differentiated allogeneic mesenchymal stem cells (iMSCs) are ~~is~~ activated by *in vitro* ~~or *ex vivo*~~ incubation with the one or more activating agents.

5. The composition of claim 1, wherein the one or more activating agents comprise one or more TLR3 agonists and the one or more TLR3 agonist is polyadenylic-polyuridylic acid (poly(A:U), polyinosine-polycytidylic acid (pIC), or a combination thereof; optionally ,wherein the concentration of the one or more TLR3 agonist is at least 10 μg/ml.

6. The composition of claim 1, wherein the one or more activating agents comprise one or

more TLR9 agonist and the one or more TLR9 agonist is CpG oligodeoxynucleotides (CpG ODNs), inhibitory oligodeoxynucleotides (ODNs) or a combination thereof.

7. The composition of claim 1, wherein the one or more activating agents comprise one or more TLR4 agonist and the one or more TLR4 agonist is bacterial lipopolysaccharides (LPS), monophosphoryl lipid A (MPLA) or a combination thereof.

8. The composition of claim 1, wherein the composition further comprises an effective amount of one or more antimicrobial agents, and wherein the one or more antimicrobial agents is a bactericidal antibiotic or a bacteriostatic antibiotic.

9. The composition of claim 8, wherein the bactericidal antibiotic is selected from the group consisting of penicillin derivatives (penams), cephalosporins (cephams), monobactams, carbapenems, vancomycin, daptomycin, fluoroquinolones, metronidazole, nitrofurantoin, co-trimoxazole, telithromycin, and aminoglycosidic antibiotics.

10. The composition of claim 8, wherein the bacteriostatic antibiotic is selected from the group consisting of tetracycline antibiotics, choloramphenicol, erythromycin, clindamycin, and linezolid, and wherein the tetracycline antibiotic is selected from the group consisting of tetracycline, doxycycline, and minocycline.

11. The composition of claim 1, wherein the allogeneic mesenchymal stem cells are human allogeneic mesenchymal stem cells.

12. The composition of claim 1, wherein the one or more activating agent is polyinosinic:polycytidylic acid (pIC); optionally, wherein the pIC is synthetic.

13. The composition of claim 1, wherein activated mesenchymal stem cells enrich monocyte recruitment to the wound site and; optionally, the recruited monocytes at the wound site differentiate into macrophages comprising M1 and M2 macrophages wherein the M2 macrophages outnumber the M1 macrophages at the wound site in the subject.

14. Use of the composition of any one of claims 1-13 in the manufacture of a medicament for treating a non-healing or chronic wound in a mammal, wherein the activated mesenchymal stem

cells treat the non-healing or chronic wound compared to mesenchymal stem cells that have not been activated according to claim 1.

15. The use of claim 14, wherein the medicament is formulated for intravenous administration.

16. The use of claim 14, wherein the non-healing or chronic wound comprises one or more of abrasions, lacerations, contusions, concussions, stab wounds, skin cuts, surgical wounds, gunshot wounds, burns, sunburns, deep-seeded or inaccessible wounds, diabetic ulcers, frostbite, chemical wounds, insect bites, animal bites, infected wound, stings and electrical wounds.

17. The use of claim 14, wherein the activated mesenchymal stem cell composition is to be administered along with or separately from, the one or more antibacterial agents or bacteriostatic antibiotic agent.

18. The use of claim 14, wherein the activated mesenchymal stem cell composition does not contain an antimicrobial agent and the composition is to be administered to a subject having a chronic wound already undergoing a treatment regimen comprising an antimicrobial agent.

19. The use of claim 14, wherein the non-healing or chronic wound comprises at least one of a non-healing or a chronic wound harboring more than one pathogenic microorganism and a non-healing or a chronic wound infected with at least one drug resistant microorganism.

20. The use of claim 14, comprising the at least one of mammalian allogeneic mesenchymal stem cells and differentiated allogeneic mesenchymal stem cells that have been exposed to a Toll-like receptor 3 (TLR3) ligand for treating a chronically bacterial-infected wound in a mammal, wherein the composition is to be administered intravenously to the mammal daily, bi-weekly, weekly, every 10 days, every 2 weeks, or once a month for about 1 to about 10 doses; and wherein an antimicrobial agent is to be administered before during or after each activated mammalian allogeneic mesenchymal stem cells or activated differentiated allogeneic mesenchymal stem cell dose.

21. The use of any one of claims 14-20, comprising an antimicrobial selected from the group consisting of one or more cephlasporins, penicillins, quinolones, tetracyclines, metronidazole,

aminoglycosides or combinations thereof.

22. A kit comprising the pharmaceutical composition of any one of claims 1-13; and at least one container.